YOLFTbeta
Hualan Biological Bacterin Inc.

Hualan Biological Bacterin Inc.

301207 · SHE · Healthcare / Biotechnology

14.67CNY-0.52 (-3.42%)

Price History

Full chart

Market Stats

Previous Close15.19
Open15.14
Day Range14.56 – 15.25
52-Week Range15.43 – 26.61
Volume4.25M
Market Cap12.09B
P/E (TTM)60.94
Forward P/E0.00
EPS0.33
Dividend Yield7.96%
Beta0.60
50-Day Avg17.96
200-Day Avg18.92

About

Hualan Biological Vaccine Inc. engages in the research and development, production, and sale of vaccines and genetically engineered biological products in China. The company's main products include influenza virus split vaccine, quadrivalent influenza virus split vaccine, quadrivalent influenza virus split vaccine (pediatric formulation), H1N1 influenza A virus split vaccine, ACYW135 group meningococcal polysaccharide vaccine, recombinant hepatitis B vaccine (Hansenula polymorpha), group A and C meningococcal polysaccharide vaccine, freeze-dried human rabies vaccine (Vero cells), and adsorbed tetanus vaccine. It also offers products under development, such as freeze-dried Group A and Group C meningococcal conjugate vaccine, adsorbed cell-free tridiphtheria-tetanus combined vaccine, freeze-dried Haemophilus influenzae type b conjugate vaccine, and recombinant zoster vaccine (CHO cells), mRNA influenza vaccines, adsorbed tetanus vaccine, and novel adjuvanted influenza vaccines. In addition, it sells self-produced products. The company was founded in 2005 and is based in Xinxiang, China.

Company Details

  • SectorHealthcare
  • IndustryBiotechnology
  • CEOMs. Wenjue An
  • Employees708
  • HeadquartersJia No. 1-1, Hualan Avenue, Xinxiang, China, 453003, China
  • Websitehttps://www.hualanbacterin.com

Leadership

  • Ms. Wenjue AnGM & Director · b. 1989
  • Mr. Ke LuCFO & Secretary · b. 1984
  • Ms. Ruowen PanExecutive VP & Director · b. 1968

Financials

Income Statement

Currency: CNY2017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Revenue284.91M802.74M1.05B2.43B1.83B1.83B2.41B1.13B1.20B
Growth (%)-+181.75%+30.68%+131.30%-24.59%-0.23%+32.03%-53.21%+6.62%
Cost of Revenue119.08M129.43M210.56M288.64M354.01M369.19M382.02M286.78M266.94M
Gross Profit165.83M673.31M838.43M2.14B1.48B1.46B2.03B841.03M935.56M
Gross Margin58.21%83.88%79.93%88.10%80.65%79.78%84.15%74.57%77.80%
Operating Expense266.36M373.51M406.39M1.06B768.82M863.82M1.02B626.17M747.96M
Operating Income-100.53M299.80M432.04M1.07B706.98M592.63M1.01B214.86M187.60M
Operating Margin-35.28%37.35%41.19%44.27%38.64%32.46%41.90%19.05%15.60%
EBITDA179.32M603.84M764.88M1.12B787.17M734.72M1.15B361.13M331.37M
EBITDA Margin62.94%75.22%72.92%46.04%43.02%40.24%47.85%32.02%27.56%
Net Income-76.88M270.15M375.30M924.91M620.97M519.63M859.97M205.52M182.92M
Net Income Margin-26.98%33.65%35.78%38.12%33.94%28.46%35.68%18.22%15.21%
R&D64.02M52.98M73.04M110.94M144.13M134.64M91.11M162.64M151.30M
R&D as % of Total Revenue22.47%6.60%6.96%4.57%7.88%7.37%3.78%14.42%12.58%
Interest Expense33.47K--2.23M13.51M10.82M6.19M6.21M2.55M
Interest Expense % of Total Revenue0.01%--0.09%0.74%0.59%0.26%0.55%0.21%

Balance Sheet

Currency: CNY2017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Assets845.69M1.37B1.79B3.65B4.52B7.08B8.00B7.52B6.84B
Total Liabilities228.91M481.15M531.88M1.46B1.72B1.58B1.73B1.51B1.14B
Total Equity616.78M886.93M1.26B2.19B2.81B5.50B6.26B6.01B5.70B
Cash26.59M143.01M278.70M412.39M131.56M600.04M640.98M623.04M352.94M
Total Debt---200.00M502.27M300.18M300.18M300.18M-
Net Debt-26.59M-143.01M-278.70M-212.39M370.71M-299.86M-340.80M-322.85M-

Cash Flow

Currency: CNY2017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow22.17M94.46M275.04M693.71M569.33M288.66M888.02M468.04M357.13M
Investing Cash Flow59.01M21.19M-140.52M-753.33M-1.09B-1.76B-773.71M-61.08M-
Financing Cash Flow-100.00M--135.69M286.13M1.95B-126.09M-424.82M-
Capital Expenditure25.60M62.77M143.89M532.28M636.06M92.65M62.60M51.60M9.70M
Free Cash Flow-3.43M31.69M131.15M161.43M-66.73M196.01M825.42M416.45M347.43M
Dividends Paid100.00M--4.59M12.77M90.88M126.09M334.32M507.89M
FCF to OCF-15.45%33.55%47.68%23.27%-11.72%67.90%92.95%88.98%97.28%
Dividend Paid to FCF-2918.38%--2.84%-19.13%46.36%15.28%80.28%146.19%

Earnings

Report DateApr 29, 2022Aug 22, 2022Oct 30, 2022Mar 29, 2023Apr 21, 2023Aug 23, 2023Oct 27, 2023Mar 29, 2024Apr 25, 2024Jun 30, 2024Oct 29, 2024Dec 31, 2024Apr 27, 2025Jun 30, 2025Sep 30, 2025Dec 31, 2025Mar 31, 2026Jun 30, 2026
EPS Estimate------------------
EPS Actual-0.000.800.520.040.230.020.870.380.06-0.020.40-0.100.06-0.020.190.090.06-0.00
Surprise------------------
TimingPre-marketPre-marketAfter-hoursPre-marketAfter-hoursPre-marketAfter-hoursAfter-hoursPre-market-Pre-market-Pre-market-----

Key Statistics & Ratios

Market Cap12.09B
Enterprise Value9.90B
Trailing P/E60.94
Forward P/E0.00
Price / Sales10.18
Price / Book2.26
EPS0.33
Book Value8.85
Revenue (TTM)1.19B
Gross Profit (TTM)853.92M
EBITDA263.13M
Profit Margin16.73%
Operating Margin-144.29%
Return on Equity3.55%
Return on Assets1.15%
Shares Outstanding601.03M
Shares Float97.10M
Beta0.60
Dividend Yield7.96%
Dividend Rate1.60
Payout Ratio4.20%

Dividends

20261×
0.80Jun 15, 2026
20252×
0.60Oct 27, 20250.20Jun 17, 2025
20241×
0.60Jun 14, 2024
20231×
0.30Jun 7, 2023
20221×
0.13Jun 16, 2022

Stock Splits

  • Jun 7, 20231.5:1